ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harpoon Therapeutics Granted Orphan Drug Designation for Multiple Myeloma Treatment
January 20, 2021Harpoon Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets ... -
Harpoon Therapeutics Announces Closing of $70M Series C Financing
November 12, 2018SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Harpoon Therapeutics, Inc. ("Harpoon"), a clinical-stage immunotherapy company developing a novel class of T cell engagers
Pharma Sources Insight January 2025
